IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy (Q39961838)

2 July 2019

title

IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy (English)

1 reference

2 July 2019

1 reference

1 reference

Alain Labbe

1

1 reference

2 July 2019

Megan Nelles

2

1 reference

2 July 2019

Jagdeep Walia

3

1 reference

2 July 2019

Lintao Jia

4

1 reference

2 July 2019

Caren Furlonger

5

1 reference

2 July 2019

Takahiro Nonaka

6

1 reference

2 July 2019

Jeffrey A Medin

7

1 reference

2 July 2019

Christopher J Paige

8

1 reference

2 July 2019

publication date

1 August 2009

1 reference

2 July 2019

Journal of Cellular and Molecular Medicine

published in

1 reference

2 July 2019

volume

13

1 reference

2 July 2019

issue

8B

1 reference

2 July 2019

page(s)

1962-1976

1 reference

2 July 2019

Interferon therapy in chronic myelogenous leukemia

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Murine model of immune-mediated rejection of the acute lymphoblastic leukemia 70Z/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Cellular mechanisms of interleukin-12-mediated neuroblastoma regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Dendritic cells in a mature age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Primary antitumor immune response mediated by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

CD4 cells can be more efficient at tumor rejection than CD8 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00412.X

Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.

21 January 2018

1 reference

12 December 2020

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

1 reference

12 December 2020

Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation

1 reference

12 December 2020

Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma

1 reference

12 December 2020

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

1 reference

12 December 2020

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.

1 reference

12 December 2020

IL-12: a promising adjuvant for cancer vaccination

1 reference

12 December 2020

Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression

1 reference

12 December 2020

Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma

1 reference

12 December 2020

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

12 December 2020

Systemic therapy in metastatic renal cell carcinoma

1 reference

12 December 2020

Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses

1 reference

12 December 2020

Murine B cell leukemia line with inducible surface immunoglobulin expression

1 reference

12 December 2020

Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts

1 reference

12 December 2020

Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.

1 reference

12 December 2020

Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

1 reference

12 December 2020

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production

1 reference

12 December 2020

The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12

1 reference

12 December 2020

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

1 reference

12 December 2020

Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids

1 reference

12 December 2020

A third-generation lentivirus vector with a conditional packaging system

1 reference

12 December 2020

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

1 reference

12 December 2020

Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD

1 reference

12 December 2020

10.1111/J.1582-4934.2008.00412.X

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6512371

1 reference

2 July 2019

PubMed publication ID

18624776

1 reference

2 July 2019